The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD) by Sagvolden, Terje
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Behavioral and Brain Functions
Open Access Research
The alpha-2A adrenoceptor agonist guanfacine improves sustained 
attention and reduces overactivity and impulsiveness in an animal 
model of Attention-Deficit/Hyperactivity Disorder (ADHD)
Terje Sagvolden*
Address: Institute of Basic Medical Sciences, Department of Physiology, University of Oslo, P.O. Box 1103 Blindern, NO-0317 Oslo, Norway
Email: Terje Sagvolden* - terje.sagvolden@medisin.uio.no
* Corresponding author    
Abstract
Background: ADHD is currently defined as a cognitive/behavioral developmental disorder where
all clinical criteria are behavioral. Overactivity, impulsiveness, and inattentiveness are presently
regarded as the main clinical symptoms. There is no biological marker, but there is considerable
evidence to suggest that ADHD behavior is associated with poor dopaminergic and noradrenergic
modulation of neuronal circuits that involve the frontal lobes. The best validated animal model of
ADHD, the Spontaneously Hypertensive Rat (SHR), shows pronounced overactivity,
impulsiveness, and deficient sustained attention. While dopamine release is decreased in SHR
prefrontal cortex, norepinephrine concentrations are elevated. The noradrenergic system appears
to be hyperactive as a result of impaired alpha-2A adrenoceptor regulation. Thus, the present study
tested behavioral effects of the centrally acting alpha-2A adrenoceptor agonist guanfacine on SHR
behavior.
Methods: The present study tested behavioral effects of guanfacine at doses of 0.075, 0.15, 0.30
and 0.60 mg base/kg i.p. in both male SHRs and their controls, the Wistar Kyoto rat (WKY).
ADHD-like behavior was tested with a visual discrimination task measuring overactivity,
impulsiveness and inattentiveness.
Results: The striking impulsiveness, overactivity, and reduced sustained attention during baseline
conditions in the SHR improved by treatment with guanfacine. The most pronounced improvement
in SHR behavior was seen following the two highest doses (0.3 and 0.6 mg/kg) of guanfacine when
SHR behaviors virtually normalized. The positive effects of the drug were most marked towards
the end of the session.
Conclusion: The results indicate that guanfacine improved poor noradrenergic modulation of
neuronal circuits that involve the frontal lobes in an animal model of ADHD. The present results
support the beneficial effects of guanfacine on ADHD behavior reported clinically and
experimentally in primate models of frontal function. It is likely that guanfacine improved prefrontal
functions in the SHR. It cannot be concluded, however, that the effects of the drug are mediated
solely by norepinephrine.
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Background
Attention-deficit/hyperactivity disorder (ADHD) is cur-
rently defined as a cognitive developmental disorder
where all clinical criteria are behavioral [1]. Overactivity,
impulsiveness, and inattentiveness are presently regarded
as the main clinical symptoms.
There have been many attempts to explain the origins of
ADHD symptoms. A dual-process model [2-5] suggests
that less efficient reinforcement processes and deficient
extinction of previously reinforced behavior are funda-
mental to the problems described as response inhibition
[6] and poor executive functions [7].
ADHD is highly heritable and the genetic and neurobio-
logical causes are likely to reside in brain catecholaminer-
gic systems (for a review see [4]). Most likely, ADHD
symptoms are associated with dysregulation of dopamin-
ergic and noradrenergic modulation of neuronal circuits
that involve the frontal lobes [8,9]. Prefrontal cortical
neurons are able to hold information relevant for the next
behavior [10]. Such information may be weakened by
dysregulated dopaminergic and noradrenergic systems in
ADHD causing the deficient working memory [11] and
the need for immediacy of reinforcement [4].
Although stimulants are the drugs of choice in the treat-
ment of ADHD [12,13], more than 10% of children and
adults with ADHD do not respond to stimulants or are
unable to tolerate the side effects [13]. Consequently,
there is a need for alternatives to stimulant medication.
Guanfacine has been used as a medication for ADHD
[12,13] although the precise mechanism of action of
guanfacine in ADHD is unknown. Guanfacine appears to
mimic the effect of norepinephrine at alpha-2A adreno-
ceptors, improving prefrontal cortical cognitive functions
at the cellular and behavioral levels (for a review see [14]).
These apparent effects are also reflected in imaging studies
demonstrating increased prefrontal cortical blood flow
following administration of guanfacine [15].
The spontaneously hypertensive rat (SHR) is the best val-
idated animal model of ADHD. These rats show hyperac-
tivity, impulsiveness and deficits in sustained attention
[9,16-18]. The control strain is usually the Wistar Kyoto
Rat (WKY) as this rat is the progenitor strain and its behav-
ior is closely similar to that of other strains when tested in
operant tasks [17].
Dopamine release is decreased in SHR prefrontal cortex
and norepinephrine concentrations are elevated [19,20].
The noradrenergic system appears to be hyperactive as a
result of impaired alpha-2A adrenoceptor regulation [9].
Thus, the aim of the current study was to investigate
behavioral effects of a wide dose range of the alpha-2A
adrenoceptor agonist guanfacine hydrochloride in the
SHR animal model of ADHD.
Methods
Subjects
A total number of 32 male rats, 16 SHR and 16 WKY, par-
ticipated in this study. At the start of testing following 8
days acclimatization, the rats were 4 wk old and experi-
mentally naïve at the start of study. Young rats were
required, as ADHD primarily is a child and adolescent dis-
order. The rats were obtained from Charles River Italy
(SHR/Crl Ico). At the University of Oslo, the rats were
housed individually in 41 × 25 × 25 (height) cm transpar-
ent cages and had free access to food (Special Diet Serv-
ices, Witham, Essex, UK.).
The rats had access to water at all times before the habitu-
ation session. However, after completing the habituation
session, the rats were deprived of water for 21 hr a day.
The rats received water as reinforcers during the experi-
mental session and had free access to water for 90 min
after the experimental session. The temperature in the
housing area was ~22°C. The light in the housing area was
on from 0700 to 1900 hours. The behavioral training took
place between 1000 and 1330 hours seven days a week.
Behavioral apparatus
Sixteen Campden Instruments operant chambers were
used in the study. The animal working space in eight of
the chambers was 25 × 25 × 30 (height) cm and 25 × 25 ×
20 (height) cm in the other eight chambers. The 2.8-W
house light and a fan producing a low masking noise were
on during the entire experimental session.
During training sessions, either one or both retractable
levers were used (below). A 2.8-W cue light was located
above each lever. The rats' response consisted of pressing
one of the levers with a dead weight of at least 3 g to acti-
vate a micro-switch. The reinforcers (0.01 ml tap water)
were delivered by a liquid dipper located in a small
recessed cubicle with a 2.8-W cue light lit up when a rein-
forcer was presented. A 7 × 5 cm transparent plastic lid
separated the cubicle from the rat's working space. The rat
could easily open the lid with a light push with the nose
or paw. Each chamber was ventilated and placed in a
sound-resistant outer housing. A computer and an online
system (SPIDER, Paul Fray, Ltd., UK) recorded the behav-
ior and scheduled reinforcers (drops of water).
Before the initiation of the study, the rats were assigned a
chamber (1 through 16) and time of testing (1000 or
1200 hours) in a randomized and balanced way. The rat
was returned to its living cage after each session andBehavioral and Brain Functions 2006, 2:41 http://www.behavioralandbrainfunctions.com/content/2/1/41
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immediately given free access to water for 90 min. All ani-
mals were run seven days a week.
Response acquisition
The training period started with a single 30-min habitua-
tion session. During the habituation session, the lid
between the working space and the reinforcement cubicle
was kept open. No lever was present, no cue light above
any lever was lit and water was not delivered. The house
light was on. Following completion of the habituation
session the rats were deprived of water for 21 hr a day; this
is a moderate, but sufficient deprivation for motivating
the animal.
The habituation session was followed by two 30-min
magazine training sessions. The lid was taped open, no
levers were present, and the house light was on, but the
cue lights above the levers were not lit. The computer
delivered water on the average every 10 s independent of
the rat's behavior (a variable-time schedule). Each water
delivery was accompanied by the turning on of the cue
light in the small recessed cubicle.
In the next four sessions, the rat was trained to open the
lid to gain access to the water. The lid was not taped open,
no levers were present and the lights above the levers were
not activated. The house light was on. Each lid opening
was followed by a presentation of a single drop of water.
The cue light in the recessed cubicle was turned on when
the water was presented.
During the subsequent three sessions, lever responding
was shaped by the method of successive approximations
[21]. During the first two of these sessions, the rats learned
to press the left lever in order to receive a reinforcer after
every press. The cue light above the left lever was now lit.
The house light was on. The right lever was retracted into
the wall and the light above the right lever was not lit. On
the third session, the right lever was activated and the left
lever retracted. During this session the light above the
right lever was activated, but the light above the left lever
was turned off. The house light was on. Following this
shaping procedure the animal had acquired the appropri-
ate behavior. From now on, both levers were present. The
light above the levers shifted randomly. The light showed
the rat which lever it had to press to receive a reinforcer
("correct lever"). The next five sessions lasted for 30 min
and the reinforcers were delivered following every correct
lever press. The rat received the reinforcer immediately
after pressing the correct lever. The cue light in the
recessed cubicle was turned on when the water was pre-
sented. A concurrent extinction (EXT) schedule was
present on the wrong lever.
Final schedule
From session 16 on until the study was finished, a 180-s
Random-Interval (RI) schedule was in effect on the correct
lever. A concurrent extinction (EXT) schedule was present
on the wrong lever. A reinforcement schedule is called
multiple when two (or more) schedules are run and each
of these is signaled. Thus, a multiple Random-Interval/
Extinction (mult RI EXT) schedule was applied for testing
effects of the drugs in the present study.
During the final multiple Random-Interval/Extinction
schedule, reinforcers were delivered on average every
180s. There was neither any external stimulus signaling
that a reinforcer was programmed according to the RI
schedule, nor any external stimulus signaling the time
since the last response.
Behavioral measures
Each session was divided into five 18-min parts ("seg-
ments") in order to monitor intra-session changes in the
behavior. For each segment, each lever press was recorded
as a function of time since last response (inter-response
time, IRT). Further, the number of reinforcers delivered
was recorded for each segment.
The total number of lever presses is an expression of the
general activity level and therefore a measure of degree of
overactivity. The percentage of correct lever choices of the
total number of lever presses when the reinforcers are
delivered infrequently is a measure of sustained attention.
The number of responses with short IRTs (< 0.67 s) is a
measure of degree of impulsiveness ("cannot hold back a
response even when one knows it is an unnecessary one").
Drug administration
In order to habituate the rats to injections and check drug
effects, the rats were given a single 0.30 mg/kg injection of
guanfacine on session 44, i.e., 5 days before the first treat-
ment day. Administration of the drugs started at session
49, following behavioral stabilization. The effects of guan-
facine hydrochloride were compared with vehicle. Each
rat was dosed intraperitoneally (i.p.) at a dose volume of
1 ml/1 kg body weight of the animal ~30 min before test-
ing, with either vehicle (saline) or drug. Drugs were
administered every 3rd day. All rats received all doses
according to a balanced design.
Doses were 0.075, 0.15, 0.3, and 0.6 mg/kg guanfacine,
and were calculated as the weight of base using a conver-
sion factor of 1.15 mg hydrochloride salt as equivalent to
1.0 mg base. Dosing solutions were prepared as a solution
in physiological saline. A stock solution, 0.6 mg/ml guan-
facine, was prepared just prior to every second drug ses-
sion, i.e., every 6th weekday and kept at +4°C when not in
use. Dilutions were made just prior to dosing.Behavioral and Brain Functions 2006, 2:41 http://www.behavioralandbrainfunctions.com/content/2/1/41
Page 4 of 7
(page number not for citation purposes)
Data management and statistical procedures
The mean behavior is regarded as the drug response, and
dose-response curves are plotted for each drug and strain.
The data are processed by univariate analyses of variance
(ANOVAs) with the Statistica 5.5 program [22]. Within-
subject variables are dose and within-session segment.
Strain is a between-subject variable. Univariate ANOVAs
with Greenhouse-Geisser corrections of the univariate Fs
and the multivariate test Rao R Form 2 are reported in
order to correct for repeated measures within subjects. The
no-injection sessions are not included in the statistical
analyses, but are shown in the figures in order to facilitate
evaluation of drug effects. T-tests are used to follow up the
ANOVAs.
Results
General
SHRs showed pronounced impulsiveness, overactivity
and decreased sustained attention. These behaviors
improved and virtually normalized following the highest
doses (0.3 and 0.6 mg/kg) of guanfacine.
Acquisition
As is the case in children with ADHD, the symptoms
developed with time, but differently for the different
behaviors. The final schedule was installed on session 16.
A pronounced overactivity was seen in SHR from session
18 onwards (Figure 1, see also Additional files 1 and 2).
SHR impulsiveness, responding within 0.67 s since the
previous lever press (although such a lever press was
almost never reinforced), continued to increase in the
SHR throughout the entire study (not shown). This meas-
ure was accompanied by increased variability over days
during the course of the experiment, something that is
typical in ADHD. In order to obtain more equal variances
as required by the ANOVAs, impulsiveness was subjected
to a lg10-transformation. These transformations were
used for evaluating drug effects.
Hyperactivity
There was a pronounced hyperactivity and good behavio-
ral separation between the two strains (Figures 1 and 2).
The pronounced SHR overactivity was reduced by guanfa-
cine. Following the highest doses of the drug, 0.3 and 0.6
mg/kg, the general activity level of the SHRs approached
that of the WKY controls. The ANOVA showed main
effects of strain, F(1, 30) = 57.84, p < 0.001; dose, Green-
house-Geisser ε = 0.65, F(2.6, 78.5) = 20.3, p < 0.001; and
within-session segment, Greenhouse-Geisser ε = 0.38,
F(1.5, 55.6) = 49.8, p < 0.001, showing that SHRs were sig-
nificantly different from WKYs on this measure. There was
also a Strain x Dose interaction effect, Greenhouse-Geisser
ε = 0.65, F(2.6, 78.5) = 8.87, p < 0.001), showing a signif-
icantly different dose-response effect for guanfacine in
SHRs vs. WKYs. There was also a Strain x Dose x Within-
Session Segment interaction effect, Rao R Form 2 (4, 27) =
4.643, p < 0.006. Follow-up t-tests for independent sam-
ples showed that there was no significant difference
between the control WKYs following placebo and the
SHRs following the 0.6 mg/kg dose t(30) = 1.927 p > 0.06,
two-tailed test. There were significant differences between
the SHRs and the WKY following placebo for all the other
doses. Therefore, the 0.6 mg/kg dose was the only one that
apparently normalized SHR behavior.
Impulsiveness
The SHRs were significantly more impulsive than the WKY
controls (Figures 3 and 4). There was a drift in the baseline
of the SHR strain. The statistical effects of the drift were
reduced by lg10-transformations.
Impulsiveness was reduced by guanfacine in a dose-
related fashion in both strains. The ANOVA showed main
effects of strain, F(1, 30) = 18.51, p < 0.001; dose, Green-
house-Geisser ε = 0.61, F(2.4, 73.1) = 23.5, p < 0.001; and
within-session segment, Greenhouse-Geisser ε = 0.57,
F(2.3, 68.3) = 24.2, p < 0.001. There was no interaction
effect involving both the strain and dose variables,
because the drug appeared to have a similar effect in the
WKYs as in the SHRs. Follow-up t-tests for independent
samples showed that there was no significant difference
between the control WKYs following placebo and the
SHRs following the 0.3 and the 0.6 mg/kg doses: t(30) <
1.69 p > 0.10, two-tailed tests, although there were signifi-
cant differences between the WKYs following placebo and
the SHRs for the other doses. Therefore, the 0.3 and 0.6
mg/kg doses apparently normalized SHR behavior.
Effect of the different guanfacine doses on total number of  lever presses in SHR and WKY Figure 1
Effect of the different guanfacine doses on total number of 
lever presses in SHR and WKY. Means ± 95% confidence 
intervals.Behavioral and Brain Functions 2006, 2:41 http://www.behavioralandbrainfunctions.com/content/2/1/41
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Sustained attention
The sustained attention behavior improved throughout
the study as well as within session in both strains
although the SHR showed a consistently poorer behavior
than the WKY controls (Figures 5 and 6).
Without active drug, the SHR had a lower percent correct
lever choice, i.e., poorer sustained attention, than WKY
controls. Guanfacine improved the poor performance of
the SHR (Figure 5). The effect was more pronounced
towards the end of the session (Figure 6). The ANOVA
showed main effects of strain, F(1, 30) = 12.4, p < 0.002;
dose, Greenhouse-Geisser ε = 0.47, F(1.9, 57.0) = 6.3, p <
0.004; and within-session segment, Greenhouse-Geisser ε
= 0.84, F(3.4, 100.6) = 21.1, p < 0.001. These effects show
that the SHRs were consistently poorer than the WKY con-
trols and that both strains' behavior improved towards the
end of the 90-min sessions. There was also a Strain x Dose
interaction effect, which shows that there was a dose-
related improvement in the SHR following the drug, but
not in the WKY controls, Greenhouse-Geisser ε = 0.47,
Effect of the different guanfacine doses on sustained atten- tion, percent choice of the correct lever in SHR and WKY Figure 5
Effect of the different guanfacine doses on sustained atten-
tion, percent choice of the correct lever in SHR and WKY. 
Means ± 95% confidence intervals.
Effect of the different guanfacine doses on impulsiveness  (lg10 transformed), responding within 0.67 s following the  previous lever press, in SHR and WKY Figure 3
Effect of the different guanfacine doses on impulsiveness 
(lg10 transformed), responding within 0.67 s following the 
previous lever press, in SHR and WKY. Means ± 95% confi-
dence intervals.
Effect of the different guanfacine doses on total number of  lever presses across the five 18-min within-session segments  in SHR and WKY Figure 2
Effect of the different guanfacine doses on total number of 
lever presses across the five 18-min within-session segments 
in SHR and WKY. Means ± 95% confidence intervals.
Effect of the different guanfacine doses on impulsiveness  (lg10 transformed) across the five 18-min within-session seg- ments in SHR and WKY Figure 4
Effect of the different guanfacine doses on impulsiveness 
(lg10 transformed) across the five 18-min within-session seg-
ments in SHR and WKY. Means ± 95% confidence intervals.Behavioral and Brain Functions 2006, 2:41 http://www.behavioralandbrainfunctions.com/content/2/1/41
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F(1.9, 57.0) = 4.32, p < 0.02). There was no Strain x Dose
x Within-Session Segment interaction effect. Follow-up t-
tests for independent samples showed that there were sig-
nificant differences between the WKYs following placebo
and the SHRs following all the doses, although the 0.3
mg/kg dose came closest to normalizing SHR behavior:
t(30) = 2.129 p = 0.042, two-tailed test.
Discussion
The main clinical symptoms of ADHD are inattentiveness,
overactivity, and impulsiveness [1]. The best validated
animal model of ADHD, the SHR, showed pronounced
impulsiveness, overactivity, and reduced sustained atten-
tion during baseline conditions, and all three measures
were improved by treatment with guanfacine.
Sedation following guanfacine is reported clinically
[12,13]. Sedation could possibly explain the reduction in
SHR impulsiveness as the dose-response curves were sim-
ilar in both the WKYs and SHRs. It seems less likely, how-
ever, that sedation can explain the reduction in
hyperactivity where the dose response curve was clearly
different in the SHRs and WKYs; and highly unlikely to
explain the improvement in sustained attention in the
SHR where a decrease would be a more likely conse-
quence of sedative activity.
Without more data on the specificity of higher doses of
guanfacine, it cannot be concluded that only norepine-
phrine is affected by the doses used presently. It might be
that improved sustained attention is due to improved
noradrenergic functioning following low doses and that
the higher doses reducing overactivity and impulsiveness
may involve other neuromodulators like dopamine in
addition to norepinephrine.
In conclusion, the present results support the beneficial
effects of guanfacine on ADHD behavior reported clini-
cally [12,13] and experimentally in primate models of
frontal function [14,15,23-25]. It is likely that guanfacine
improved prefrontal functions in the SHR, cf. [14,15]. It
cannot be concluded, however, that the effects of the drug
are mediated solely by norepinephrine.
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